148617 20260218073927.0 doi 10.1016/j.arbres.2024.12.005 sideral 141351 ART-2024-141351 eng (orcid)0000-0002-5228-248X Sanz-Rubio, David Circulating Exosomal MicroRNAs and Subclinical Atherosclerosis in Obstructive Sleep Apnea 2024 Access copy available to the general public Unrestricted Background. Obstructive sleep apnea (OSA) has been associated with thepathogenesis of atherogenesis. Exosomes and their microRNA (miRNA) cargocould play a major role in this process.Objectives. To determine plasma exosomal miRNA and their relationship withatherosclerosis in patients with OSA.Methods. From the EPIOSA cohort, we selected 50 OSA patients (apnea-hypopnea index–AHI ≥ 10) and 16 age- and sex-matched healthy subjects (AHI≤ 10) for the derivation analysis. The validation assay was composed by 88 OSApatients and 24 matched controls. OSA patients were categorized according toprevalent subclinical atherosclerosis (SA) as defined by ≥ 1 plaque in carotidultrasound. All participants were free of prevalent chronic comorbid conditions.Plasma-derived exosomes were isolated by precipitation, and miRNAs wereevaluated by real-time quantitative PCR.Results. SA was present in 34% of OSA patients. Three exosomal miRNAs wereoverexpressed in patients with OSA and SA at the derivation study: miR-21(relative expression, RE = 2.91), miR-145 (RE = 2.12) and miR-320a (RE =4.06). ROC curve analysis showed a high predictive value for SA of miR-320a(area under curve AUC = 0.813). In the validation cohort, miR-320a alsoexhibited an overexpression of RE = 2.66 among patients with OSA and SA, withan AUC of 0.798. Together with AHI and APO B, miR-320a, was independentlyassociated with SA. In addition, miR-320a correlate with the progression of intimamedia thickness from baseline to after 1 year of follow-up. Finally, miR-320a wasnot reduced after 1 year of follow-up independiently of the treatment with CPAP.3Conclusions. In patients with OSA, exosomal miR-320a is associated to thepresence of subclinical atherosclerosis and could be a useful marker ofcardiovascular risk in these patients info:eu-repo/grantAgreement/ES/DGA/B22-20R info:eu-repo/grantAgreement/ES/DGA-CUS/1466-2020 info:eu-repo/grantAgreement/ES/ISCIII CD22-00033 info:eu-repo/grantAgreement/ES/ISCIII/PI15-01441 info:eu-repo/grantAgreement/ES/ISCIII/PI18-01524 info:eu-repo/grantAgreement/ES/ISCIII/PI21-01954 info:eu-repo/grantAgreement/ES/MICINN/RYC2019--027831-I info:eu-repo/semantics/openAccess by-nc-nd https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es 9.2 2024 RESPIRATORY SYSTEM 6 / 108 = 0.056 2024 Q1 T1 0.466 2024 Pulmonary and Respiratory Medicine 2024 Q3 3.5 2024 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion (orcid)0000-0001-6016-4726 Martín-Burriel, Inmaculada Universidad de Zaragoza (orcid)0000-0001-6351-0444 Rodríguez, Jorge Universidad de Zaragoza (orcid)0000-0003-0777-3850 Marín-Oto, Marta Universidad de Zaragoza Khalyfa, Abdelnaby Sánchez-de-la-Torre, Manuel Gozal, David (orcid)0000-0001-9096-2294 Marin, Jose M. Universidad de Zaragoza 1001 420 Universidad de Zaragoza Dpto. Anatom.,Embri.Genét.Ani. Área Genética 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 61, 4 (2024), 235-238 Arch. bronconeumol. Archivos de Bronconeumologia 0300-2896 638968 http://zaguan.unizar.es/record/148617/files/texto_completo.pdf Postprint info:eu-repo/date/embargoEnd/2026-01-09 1205652 http://zaguan.unizar.es/record/148617/files/texto_completo.jpg?subformat=icon icon Postprint info:eu-repo/date/embargoEnd/2026-01-09 oai:zaguan.unizar.es:148617 articulos driver 2026-02-17-20:34:44 ARTICLE